Table 2.
Support measures offered during the course of SARS-CoV-2 infection a
| Support measure | Control group (n = 71) | Ribavirin group (n = 44) | P-value |
|---|---|---|---|
| Immunoglobulin therapy | 0.143 | ||
| No | 46 (64.8) | 33 (75.0) | |
| Yes | 25 (35.2) | 11 (25.0) | |
| Non-invasive ventilation support | 0.750 | ||
| No | 53 (74.6) | 34 (77.3) | |
| Yes | 18 (25.4) | 10 (22.7) | |
| Invasive ventilation support | 0.302 | ||
| No | 64 (90.1) | 42 (95.5) | |
| Yes | 7 (9.9) | 2 (4.5) | |
| Corticosteroid therapy b | 0.288 | ||
| No | 45 (65.2) | 30 (75.0) | |
| Yes | 24 (34.8) | 10 (25.0) | |
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Data are presented as n (%).
b
There were missing data for immunoglobulin therapy and corticosteroid therapy.